CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 305 enrolled
Drug / intervention
Cinacalcetdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00928408
NCT00928408N/ACompleted

PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice

Amgen·observational·Posted Jun 26, 2009·Updated Aug 1, 2018

In Brief

An observational study evaluating Cinacalcet for Hyperparathyroidism, Primary. Completed, enrolled 305 participants.

Detailed Summary

This is a multicentre, descriptive observational study of adult patients with primary HPT receiving cinacalcet in clinical practice in a number of countries in Europe. Patients will be enrolled within 1 month of initiating cinacalcet treatment, and data will be collected prospectively for up to 1 year from initiation. Data will continue to be collected from patients discontinuing cinacalcet before the end of this period.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 26, 2009
Enrollment StartOct 1, 2009
Primary CompletionDec 1, 2011
Study CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 17.0 years ago

Interventions

Cinacalcetdrug